Snus: Difference between revisions
Richardpruen (talk | contribs) →Properties: Added history page |
Richardpruen (talk | contribs) →Potential benefits of Snus: Edit passage for clarity |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__TOC__ | __TOC__ | ||
[[File:323B3915-10EF-4945-AAA2-3EED42737C04.jpeg | [[File:323B3915-10EF-4945-AAA2-3EED42737C04.jpeg|alt=A can of Siberia Snus, showing the contained pouches and container lid|right|frameless|300x300px]] | ||
== Description == | == Description == | ||
Snus is a tobacco product (pouch) which the user places in the mouth between the gum and cheek. No combustion is involved. Once in place, the saliva and general moistness of the mouth work to release the nicotine into the system. This process does not require any form of combustion. For other smokeless tobacco products try the [[SLT]] page. | Snus is a tobacco product (pouch) which the user places in the mouth between the gum and cheek. No combustion is involved. Once in place, the saliva and general moistness of the mouth work to release the nicotine into the system. This process does not require any form of combustion. For other smokeless tobacco products try the [[SLT]] page. | ||
| Line 15: | Line 16: | ||
* Lower nicotine likely implies lower dependency profile than cigarettes, because of slower nicotine absorption (akin to gums). | * Lower nicotine likely implies lower dependency profile than cigarettes, because of slower nicotine absorption (akin to gums). | ||
* Should be stored in the fridge, if infrequently used. | * Should be stored in the fridge, if infrequently used. This is to prevent microbes, these can result in nitrosamines from metabolic processes. Dry Snus is more suitable/stable if refrigeration is not available. | ||
=== Potential benefits of Snus === | === Potential benefits of Snus === | ||
* Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | * Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking | ||
* Snus poses no respiratory risk. | * Snus poses no respiratory risk. It cannot cause respiratory diseases, predominantly lung cancer, chronic obstructive pulmonary disease tobacco smoke does, nothing is inhaled. | ||
* Low risk oral nicotine product. | * Low risk oral nicotine product. | ||
* Highly effective way of quitting cigarettes. | * Highly effective way of quitting cigarettes. | ||
| Line 41: | Line 42: | ||
=== Africa === | === Africa === | ||
Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco is used more often. | Snus may be banned in some locations, legal in others. It's use is not common, other more harmful oral tobacco [[SLT|(see SLT)]] is used more often. | ||
=== Europe === | === Europe === | ||
| Line 75: | Line 76: | ||
== Studies general information == | == Studies general information == | ||
==== 2024:[https://link.springer.com/epdf/10.1186/s12954-024-01095-7?sharing_token=_1R3Pf6IlmYuu1rCO8WKR2_BpE1tBhCbnbw3BuzI2ROn4zJn13QApxXLzZ1Nm2EMUkgR9kBcTUj-17Nn5d2sQs8mLy3R96OBBGptbTCRJIWB4pPY-WWLKJ0DqqKOq-LBdg_MBr5Q2Y15L5xIyeK8sAjjshzb6jigkC1RlZKharE%3D If there had been no snus in Sweden: the impact of snus on mortality attributable to smoking] ==== | |||
* It is made up by comparisons between observed Swedish data and two scenarios without snus: a group of comparable countries, and, a hypothetical Sweden with no snus use. | |||
* Both comparisons suggest that around 3000 lives per year have been saved by the use of snus in Sweden. | |||
* The potential of snus to reduce smoking-attributable mortality can be elucidated by comparing Swedish data on smoking-attributable mortality with corresponding data from comparable countries with virtually no snus. Switzerland and most EU countries outside Sweden | |||
==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ==== '''2022:''' [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ==== | ||
| Line 186: | Line 193: | ||
===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]=== | ||
[[ | [[Category:THR product]] | ||
[[ | [[Category:Smoking cessation]] | ||